You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumoniaSBC: Arrevus, Inc. Topic: NIAID
Project SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.SBC: EARNANO LLC Topic: NICHD
Otitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Periomics Care LLC Topic: NIDCR
Abstract Periodontitis is a common chronic inflammatory disease characterized by destruction of the supporting structures of the teeththe periodontal ligament and alveolar boneThe total prevalence of periodontitis in adults agedyears and older wasrepresenting aboutmillion adults agedyears and olderandin adults agedyears and older in the U SEpidemiological data confirm that diabetes is a major risk ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Irex Pharma LLC Topic: NIAID
PROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: POINT DESIGNS, LLC Topic: NICHD
The Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Technology Commercialization Partners LLC Topic: OD
PROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: LEXEO Therapeutics LLC Topic: 400
AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene therapy strategy as a preventative therapy to protect individuals with aldehyde dehydrogenaseALDHdeficiency from the high risk for esophageal cancerAs the next step in the development paththe goal of this ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Cytex Therapeutics, Inc. Topic: NIAMS
ABSTRACT Rotator cuff repairRCRis a common first line surgical solution to symptomatic rotator cuff injurywith overRCRs performed annuallyand growing at a rate ofUnfortunatelyof the cases are complicated by failure and re tear of the repaired tendonwhich commonly results in a significant reduction in activities of daily livingworkand or sports and recreation for the patient due to pain and restric ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Establishing a mechanistic foundation for drug discovery: The ABCA4 transporter in Stargardt Disease and other retinopathiesSBC: Rectify Pharmaceuticals LLC Topic: NEI
ABCAis an ABC transporter found in retinal photoreceptor cellsMutations in ABCAhave been implicated in retinopathies such as autosomal recessive Stargardt macular degenerationcone rod dystrophyretinitis pigmentosa and age related macular degenerationABCAfunctions as an importerandflippasemoving N retinylidene phosphatidylethanolamineN retinylidene PEfrom the lumen to the cytoplasmic leaflet of dis ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
A portable multi-parametric optical spectroscopy device for key vascular and metabolic endpoints monitoring in small animalsSBC: Zenalux Biomedical, Inc. Topic: OD
Altered vascularity and deregulated metabolism are two important cancer hallmarksInterest in therapeutically exploiting these functional endpoints continues to growsince metabolism and vasculature significantly impact a tumor s fateThere is growing demand for systems level technologies that measure tumor metabolism within an intact microenvironment to inform strategies to prevent resistancerecurre ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health